$ILMN & $PACB mutually agree to terminate $1.2B merger agreement, citing "lengthy regulatory approval process." Illumina to pay Pac Bio $98m termination fee:https://www.businesswire.com/news/home/20200102005512/en/ …
-
2/2 it's ironic (or worse) to see stoppage of a deal that actually could accelerate use of really exacting ultra high quality sequencing for people with
#cancer and novel variants. On cancer lives lost to reg. delays, see Dr. David Stewart's calculations. https://www.ascopost.com/issues/october-25-2015/delays-in-drug-approval-are-deadly-highlighting-the-need-for-improved-regulatory-efficiency/ …
